For the liver, GLP-1 has been found to inhibit the deposition of liver fat (90), and further research has confirmed that its antagonists may be beneficial for the treatment of NAFLD (91). This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.